Sagefield Capital’s Amicus Therapeutics FOLD Stock Holding History

Sagefield Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,021,016	Closed	-$14.8M	–	123
2026 Q1	$14.8M	Buy	+1,021,016	New	+$14.6M	1.06%	27

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Sagefield Capital's FOLD Position: Q2 2026 in Review

Sagefield Capital sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 1,021,016 shares — an estimated $14.8M sold.

Sagefield Capital first reported a position in FOLD in Q1 2026 and held it in 1 quarter. The position peaked at $14.8M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Sagefield Capital reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Sagefield Capital sold 1,021,016 Amicus Therapeutics shares in Q2 2026, an estimated $14.8M.
Sagefield Capital first reported a position in Amicus Therapeutics in Q1 2026 and held it in 1 quarter.
Sagefield Capital's Amicus Therapeutics position peaked at $14.8M in Q1 2026.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Sagefield Capital's 13F filing for Q2 2026, filed 14 Aug 2026.